Abstract

Space travel induces stresses that contribute to health problems, as well as inducing the expression of Nrf2 (NF-E2-related factor-2) target genes that mediate adaptive responses to oxidative and other stress responses. The volume of epididymal white adipose tissue (eWAT) in mice increases during spaceflight, a change that is attenuated by Nrf2 knockout. We conducted metabolome analyses of plasma from wild-type and Nrf2 knockout mice collected at pre-flight, in-flight and post-flight time points, as well as tissues collected post-flight to clarify the metabolic responses during and after spaceflight and the contribution of Nrf2 to these responses. Plasma glycerophospholipid and sphingolipid levels were elevated during spaceflight, whereas triacylglycerol levels were lower after spaceflight. In wild-type mouse eWAT, triacylglycerol levels were increased, but phosphatidylcholine levels were decreased, and these changes were attenuated in Nrf2 knockout mice. Transcriptome analyses revealed marked changes in the expression of lipid-related genes in the liver and eWAT after spaceflight and the effects of Nrf2 knockout on these changes. Based on these results, we concluded that space stress provokes significant responses in lipid metabolism during and after spaceflight; Nrf2 plays critical roles in these responses.

Akira Uruno et al. report the volume of epidydimal white adipose tissue and plasma glycerophospholipid and sphingolipid levels in mice increase during spaceflight. These metabolic and physiological changes were largely driven by Nrf2 (NF-E2-related factor-2), ultimately providing a mechanistic target for altering lipid metabolism on Earth and the Great Beyond.

Details

Title
Nrf2 plays a critical role in the metabolic response during and after spaceflight
Author
Uruno Akira 1   VIAFID ORCID Logo  ; Saigusa Daisuke 1 ; Suzuki, Takafumi 2   VIAFID ORCID Logo  ; Yumoto Akane 3 ; Nakamura, Tomohiro 4 ; Matsukawa, Naomi 5 ; Yamazaki Takahiro 6 ; Saito Ristumi 1 ; Taguchi Keiko 7   VIAFID ORCID Logo  ; Suzuki, Mikiko 8   VIAFID ORCID Logo  ; Suzuki, Norio 9   VIAFID ORCID Logo  ; Otsuki Akihito 1   VIAFID ORCID Logo  ; Katsuoka Fumiki 7   VIAFID ORCID Logo  ; Hishinuma Eiji 10 ; Okada Risa 3 ; Koshiba Seizo 10 ; Tomioka Yoshihisa 6 ; Shimizu Ritsuko 11   VIAFID ORCID Logo  ; Shirakawa Masaki 3 ; Kensler, Thomas W 12   VIAFID ORCID Logo  ; Shiba Dai 13   VIAFID ORCID Logo  ; Yamamoto Masayuki 1   VIAFID ORCID Logo 

 Tohoku University, Department of Integrative Genomics, Tohoku Medical Megabank Organization, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943); Tohoku University Graduate School of Medicine, Department of Medical Biochemistry, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943) 
 Tohoku University Graduate School of Medicine, Department of Medical Biochemistry, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943) 
 JEM Utilization Center, Human Spaceflight Technology Directorate, JAXA, Tsukuba, Japan (GRID:grid.69566.3a) 
 Tohoku University, Department of Health Record Informatics, Tohoku Medical Megabank Organization, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943) 
 Tohoku University, Department of Integrative Genomics, Tohoku Medical Megabank Organization, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943) 
 Tohoku University, Laboratory of Oncology, Pharmacy Practice and Sciences, Graduate School of Pharmaceutical Sciences, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943) 
 Tohoku University, Department of Integrative Genomics, Tohoku Medical Megabank Organization, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943); Tohoku University Graduate School of Medicine, Department of Medical Biochemistry, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943); Tohoku University, Advanced Research Center for Innovations in Next-GEneration Medicine (INGEM), Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943) 
 Tohoku University Graduate School of Medicine, Department of Medical Biochemistry, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943); Tohoku University Graduate School of Medicine, Center for Radioisotope Sciences, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943) 
 Tohoku University Graduate School of Medicine, Division of Oxygen Biology, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943) 
10  Tohoku University, Department of Integrative Genomics, Tohoku Medical Megabank Organization, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943); Tohoku University, Advanced Research Center for Innovations in Next-GEneration Medicine (INGEM), Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943) 
11  Tohoku University, Department of Integrative Genomics, Tohoku Medical Megabank Organization, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943); Tohoku University Graduate School of Medicine, Department of Molecular Hematology, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943) 
12  Translational Research Program, Fred Hutchinson Cancer Research Center, Seattle, USA (GRID:grid.270240.3) (ISNI:0000 0001 2180 1622) 
13  JEM Utilization Center, Human Spaceflight Technology Directorate, JAXA, Tsukuba, Japan (GRID:grid.270240.3) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
23993642
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2608260749
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.